Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment
| Autor: | Elizabeth A. Grimm, Cindy S. Hwang, Abdul H. Diwan, Gregory Lizée, Patrick Hwu, Omar Eton, Victor G. Prieto, Sandra A. Kinney, Kevin B. Kim, Ping Liu, Julie A. Ellerhorst, Suhendan Ekmekcioglu |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Cancer Research
Pathology medicine.medical_specialty medicine.medical_treatment Dermatology Article Piperazines Targeted therapy hemic and lymphatic diseases Humans Medicine Extracellular Signal-Regulated MAP Kinases Melanoma Protein kinase B PI3K/AKT/mTOR pathway Tissue microarray business.industry Imatinib medicine.disease Pyrimidines Imatinib mesylate Oncology Tissue Array Analysis Benzamides Imatinib Mesylate Cancer research Immunohistochemistry business Proto-Oncogene Proteins c-akt Signal Transduction medicine.drug |
| Zdroj: | Melanoma Research. 18:241-245 |
| ISSN: | 0960-8931 |
| DOI: | 10.1097/cmr.0b013e3283046146 |
| Popis: | Response to treatment with imatinib mesylate has been associated in preclinical models with the inhibition of two signaling pathways that promote cellular survival - the phosphatidylinositol 3-kinase/AKT pathway and the mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) pathway. We sought to evaluate the extent of inhibition of these two pathways in metastatic melanoma specimens from patients treated with imatinib. Metastatic melanoma tumor samples were obtained before and during the second week of imatinib treatment from patients enrolled in a phase II study. A tissue microarray was constructed using formalin-fixed, paraffin-embedded tissues, and immunohistochemical analysis was performed using standard techniques to detect phosphorylated (p) ERK1/2 and pAKT expression. Of 21 patients who were treated with imatinib, tumor samples adequate for analysis were available both at baseline and during the second week of treatment from 10 patients for pERK1/2 expression and from nine patients for pAKT expression. No consistent pattern of change in pAKT or pERK expression after treatment with imatinib was observed. No apparent correlation between the clinical benefit of imatinib treatment and changes in pAKT and pERK1/2 expression was observed. A better understanding of the AKT and mitogen-activated protein kinase pathways is needed to optimize the clinical benefit of targeted therapy, such as imatinib. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|